Plant-derived neuroprotective agents in Parkinson’s disease

American Journal of Translational Research

Volumn 7, Issue 7, 2015, Pages 1189-1202

  Fu, Wenyu ^a   Zhuang, Wenxin ^a   Zhou, Shuanhu ^b   Wang, Xin ^b  

^a WEIFANG MEDICAL UNIVERSITY   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Chinese herbs; Curcumin; Ginsenoside; Neuroprotection; Parkinson s disease; Resveratrol

Indexed keywords

C REACTIVE PROTEIN; CASPASE 3; CURCUMIN; CYCLOOXYGENASE 2; GINSENOSIDE; GLUTATHIONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12P40; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PHOSPHOLIPASE A2; PROTEIN BAX; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; RESVERATROL; SIRTUIN 1; STRESS ACTIVATED PROTEIN KINASE; SUPPRESSOR OF CYTOKINE SIGNALING 1; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA; TYROSINE 3 MONOOXYGENASE; UNINDEXED DRUG;

ANTIOXIDANT ACTIVITY; APOPTOSIS; CELL FUNCTION; CHINESE MEDICINE; DISEASE COURSE; DOPAMINERGIC NERVE CELL; HEREDITY; HUMAN; INFLAMMATION; MITOCHONDRIAL DYSFUNCTION; MITOCHONDRIAL MEMBRANE POTENTIAL; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SUBSTANTIA NIGRA;

EID: 84939556767     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. [1] Dauer W and Przedborski S. Parkinson’s disease: mechanisms and models. Neuron 2003; 39: 889-909.
2. [2] Fu W, Zheng Z, Zhuang W, Chen D, Wang X, Sun X and Wang X. Neural metabolite changes in corpus striatum after rat multipotent mesenchymal stem cells transplanted in hemiparkinsonian rats by magnetic resonance spectroscopy. Int J Neurosci 2013; 123: 883-891.
3. [3] Buzhor E, Leshansky L, Blumenthal J, Barash H, Warshawsky D, Mazor Y and Shtrichman R. Cell-based therapy approaches: the hope for incurable diseases. Regen Med 2014; 9: 649-672.
4. [4] Virmani A, Pinto L, Binienda Z and Ali S. Food, nutrigenomics, and neurodegeneration--neuroprotection by what you eat! Mol Neurobiol 2013; 48: 353-362.
5. [5] Lee WH, Loo CY, Bebawy M, Luk F, Mason RS and Rohanizadeh R. Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century. Curr Neuropharmacol 2013; 11: 338-378.
6. [6] Kim HJ, Kim P and Shin CY. A comprehensive review of the therapeutic and pharmacological effects of ginseng and ginsenosides in central nervous system. J Ginseng Res 2013; 37: 8-29.
7. [7] Sun AY, Wang Q, Simonyi A and Sun GY. Resveratrol as a therapeutic agent for neurodegenerative diseases. Mol Neurobiol 2010; 41: 375-383.
8. [8] Chen LW, Wang YQ, Wei LC, Shi M and Chan YS. Chinese herbs and herbal extracts for neuroprotection of dopaminergic neurons and potential therapeutic treatment of Parkinson’s disease. CNS Neurol Disord Drug Targets 2007; 6: 273-281.
9. [9] Zhang F, Shi JS, Zhou H, Wilson B, Hong JS and Gao HM. Resveratrol protects dopamine neurons against lipopolysaccharide-induced neurotoxicity through its anti-inflammatory actions. Mol Pharmacol 2010; 78: 466-477.
10. [10] Wight RD, Tull CA, Deel MW, Stroope BL, Eubanks AG, Chavis JA, Drew PD and Hensley LL. Resveratrol effects on astrocyte function: relevance to neurodegenerative diseases. Biochem Biophys Res Commun 2012; 426: 112-115.
11. [11] Zhang F, Wang YY, Liu H, Lu YF, Wu Q, Liu J and Shi JS. Resveratrol Produces Neurotrophic Effects on Cultured Dopaminergic Neurons through Prompting Astroglial BDNF and GDNF Release. Evid Based Complement Alternat Med 2012; 2012: 937605.
12. [12] Renaud J, Bournival J, Zottig X and Martinoli MG. Resveratrol protects DAergic PC12 cells from high glucose-induced oxidative stress and apoptosis: effect on p53 and GRP75 localization. Neurotox Res 2014; 25: 110-123.
13. [13] Chao J, Yu MS, Ho YS, Wang M and Chang RC. Dietary oxyresveratrol prevents parkinsonian mimetic 6-hydroxydopamine neurotoxicity. Free Radic Biol Med 2008; 45: 1019-1026.
14. [14] Su X and Federoff HJ. Immune responses in Parkinson’s disease: interplay between central and peripheral immune systems. Biomed Res 2014; 2014: 275178.
15. [15] Liu L, Arun A, Ellis L, Peritore C and Donmez G. SIRT2 enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced nigrostriatal damage via apoptotic pathway. Front Aging Neurosci 2014; 6: 184.
16. [16] Radi E, Formichi P, Battisti C and Federico A. Apoptosis and oxidative stress in neurodegenerative diseases. J Alzheimers Dis 2014; 42 Suppl 3: S125-152.
17. [17] Frankel D and Schipper HM. Cysteamine pretreatment of the astroglial substratum (mitochondrial iron sequestration) enhances PC12 cell vulnerability to oxidative injury. Exp Neurol 1999; 160: 376-385.
18. [18] Bureau G, Longpre F and Martinoli MG. Resveratrol and quercetin, two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation. J Neurosci Res 2008; 86: 403-410.
19. [19] Jin F, Wu Q, Lu YF, Gong QH and Shi JS. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson’s disease in rats. Eur J Pharmacol 2008; 600: 78-82.
20. [20] Lofrumento DD, Nicolardi G, Cianciulli A, De Nuccio F, La Pesa V, Carofiglio V, Dragone T, Calvello R and Panaro MA. Neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson’s-like disease: possible role of SOCS-1 in reducing pro-inflammatory responses. Innate Immun 2014; 20: 249-260.
21. [21] Chang CY, Choi DK, Lee DK, Hong YJ and Park EJ. Resveratrol confers protection against rotenone-induced neurotoxicity by modulating myeloperoxidase levels in glial cells. PLoS One 2013; 8: e60654.
22. [22] Ye J, Liu Z, Wei J, Lu L, Huang Y, Luo L and Xie H. Protective effect of SIRT1 on toxicity of microglial-derived factors induced by LPS to PC12 cells via the p53-caspase-3-dependent apoptotic pathway. Neurosci Lett 2013; 553: 72-77.
23. [23] Pallas M, Casadesus G, Smith MA, Coto-Montes A, Pelegri C, Vilaplana J and Camins A. Resveratrol and neurodegenerative diseases: activation of SIRT1 as the potential pathway towards neuroprotection. Curr Neurovasc Res 2009; 6: 70-81.
24. [24] Chao J, Li H, Cheng KW, Yu MS, Chang RC and Wang M. Protective effects of pinostilbene, a resveratrol methylated derivative, against 6-hydroxydopamine-induced neurotoxicity in SHSY5Y cells. J Nutr Biochem 2010; 21: 482-489.
25. [25] Gerhardt E, Graber S, Szego EM, Moisoi N, Martins LM, Outeiro TF and Kermer P. Idebenone and resveratrol extend lifespan and improve motor function of HtrA2 knockout mice. PLoS One 2011; 6: e28855.
26. [26] Makhija DT and Jagtap AG. Studies on sensitivity of zebrafish as a model organism for Parkinson’s disease: Comparison with rat model. J Pharmacol Pharmacother 2014; 5: 39-46.
27. [27] Bournival J, Quessy P and Martinoli MG. Protective effects of resveratrol and quercetin against MPP+-induced oxidative stress act by modulating markers of apoptotic death in dopaminergic neurons. Cell Mol Neurobiol 2009; 29: 1169-1180.
28. Rasouri S, Lagouge M and Auwerx J. [SIRT1/PGC-1: a neuroprotective axis?]. Med Sci (Paris) 2007; 23: 840-844.
29. [29] Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B and Sinclair DA. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003; 425: 191-196.
30. [30] Baur JA and Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 5: 493-506.
31. [31] Dasgupta B and Milbrandt J. Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci U S A 2007; 104: 7217-7222.
32. [32] Fuenzalida K, Quintanilla R, Ramos P, Piderit D, Fuentealba RA, Martinez G, Inestrosa NC and Bronfman M. Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis. J Biol Chem 2007; 282: 37006-37015.
33. [33] Wu JS, Cheung WM, Tsai YS, Chen YT, Fong WH, Tsai HD, Chen YC, Liou JY, Shyue SK, Chen JJ, Chen YE, Maeda N, Wu KK and Lin TN. Ligand-activated peroxisome proliferator-activated receptor-gamma protects against ischemic cerebral infarction and neuronal apoptosis by 14-3-3 epsilon upregulation. Circulation 2009; 119: 1124-1134.
34. [34] Tang BL and Chua CE. SIRT1 and neuronal diseases. Mol Aspects Med 2008, 29: 187-200.
35. [35] Wu Y, Li X, Zhu JX, Xie W, Le W, Fan Z, Jankovic J and Pan T. Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson’s disease. Neurosignals 2011; 19: 163-174.
36. [36] Jeong JK, Moon MH, Bae BC, Lee YJ, Seol JW, Kang HS, Kim JS, Kang SJ and Park SY. Autophagy induced by resveratrol prevents human prion protein-mediated neurotoxicity. Neurosci Res 2012; 73: 99-105.
37. [37] Long J, Gao H, Sun L, Liu J and Zhao-Wilson X. Grape extract protects mitochondria from oxidative damage and improves locomotor dysfunction and extends lifespan in a Drosophila Parkinson’s disease model. Rejuvenation Res 2009; 12: 321-331.
38. [38] Khan MM, Ahmad A, Ishrat T, Khan MB, Hoda MN, Khuwaja G, Raza SS, Khan A, Javed H, Vaibhav K and Islam F. Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson’s disease. Brain Res 2010; 1328: 139-151.
39. [39] Zahid M, Saeed M, Yang L, Beseler C, Rogan E and Cavalieri EL. Formation of dopamine quinone-DNA adducts and their potential role in the etiology of Parkinson’s disease. IUBMB Life 2011; 63: 1087-1093.
40. [40] Wang Y, Xu H, Fu Q, Ma R and Xiang J. Protective effect of resveratrol derived from Polygonum cuspidatum and its liposomal form on nigral cells in parkinsonian rats. J Neurol Sci 2011; 304: 29-34.
41. [41] Wu PF, Xie N, Zhang JJ, Guan XL, Zhou J, Long LH, Li YL, Xiong QJ, Zeng JH, Wang F and Chen JG. Resveratrol preconditioning increases methionine sulfoxide reductases A expression and enhances resistance of human neuroblastoma cells to neurotoxins. J Nutr Biochem 2013; 24: 1070-1077.
42. [42] Rubiolo JA, Mithieux G and Vega FV. Resveratrol protects primary rat hepatocytes against oxidative stress damage: activation of the Nrf2 transcription factor and augmented activities of antioxidant enzymes. Euro J Pharmacol 2008; 591: 66-72.
43. [43] Bi XL, Yang JY, Dong YX, Wang JM, Cui YH, Ikeshima T, Zhao YQ and Wu CF. Resveratrol inhibits nitric oxide and TNF-alpha production by lipopolysaccharide-activated microglia. Int Immunopharmacol 2005; 5: 185-193.
44. [44] Sun AY, Wang Q, Simonyi A and Sun GY. Botanical phenolics and brain health. Neuromolecular Med 2008; 10: 259-274.
45. [45] Mudo G, Makela J, Di Liberto V, Tselykh TV, Olivieri M, Piepponen P, Eriksson O, Malkia A, Bonomo A, Kairisalo M, Aguirre JA, Korhonen L, Belluardo N and Lindholm D. Transgenic expression and activation of PGC-1alpha protect dopaminergic neurons in the MPTP mouse model of Parkinson’s disease. Cell Mol Life Sci 2012; 69: 1153-1165.
46. [46] Ferretta A, Gaballo A, Tanzarella P, Piccoli C, Capitanio N, Nico B, Annese T, Di Paola M, Dell’aquila C, De Mari M, Aguirre JA, Korhonen L, Belluardo N and Lindholm D. Effect of resveratrol on mitochondrial function: implications in parkin-associated familiar Parkinson’s disease. Biochim Biophys Acta 2014; 1842: 902-915.
47. [47] Srivastava G, Dixit A, Yadav S, Patel DK, Prakash O and Singh MP. Resveratrol potentiates cytochrome P450 2 d22-mediated neuroprotection in maneb-and paraquat-induced parkinsonism in the mouse. Free Radic Biol Med 2012; 52: 1294-1306.
48. [48] Wang J, Du XX, Jiang H and Xie JX. Curcumin attenuates 6-hydroxydopamine-induced cytotoxicity by anti-oxidation and nuclear factorkappa B modulation in MES23.5 cells. Biochem Pharmacol 2009; 78: 178-183.
49. [49] Yang S, Zhang D, Yang Z, Hu X, Qian S, Liu J, Wilson B, Block M and Hong JS. Curcumin protects dopaminergic neuron against LPS induced neurotoxicity in primary rat neuron/glia culture. Neurochem Res 2008; 33: 2044-2053.
50. [50] Ojha RP, Rastogi M, Devi BP, Agrawal A and Dubey GP. Neuroprotective effect of curcuminoids against inflammation-mediated dopaminergic neurodegeneration in the MPTP model of Parkinson’s disease. J Neuroimmune Pharmacol 2012; 7: 609-618.
51. [51] Tripanichkul W and Jaroensuppaperch EO. Ameliorating effects of curcumin on 6-OHDAinduced dopaminergic denervation, glial response, and SOD1 reduction in the striatum of hemiparkinsonian mice. Eur Rev Med Pharmacol Sci 2013; 17: 1360-1368.
52. [52] Tegenge MA, Rajbhandari L, Shrestha S, Mithal A, Hosmane S and Venkatesan A. Curcumin protects axons from degeneration in the setting of local neuroinflammation. Exp Neurol 2014; 253: 102-110.
53. [53] Chen J, Tang XQ, Zhi JL, Cui Y, Yu HM, Tang EH, Sun SN, Feng JQ and Chen PX. Curcumin protects PC12 cells against 1-methyl-4-phenylpyridinium ion-induced apoptosis by bcl-2-mitochondria-ROS-iNOS pathway. Apoptosis 2006; 11: 943-953.
54. [54] Wang MS, Boddapati S, Emadi S and Sierks MR. Curcumin reduces alpha-synuclein induced cytotoxicity in Parkinson’s disease cell model. BMC Neurosci 2010; 11: 57.
55. [55] Pan J, Li H, Ma JF, Tan YY, Xiao Q, Ding JQ and Chen SD. Curcumin inhibition of JNKs prevents dopaminergic neuronal loss in a mouse model of Parkinson’s disease through suppressing mitochondria dysfunction. Transl Neurodegener 2012; 1: 16.
56. Chiu S, Terpstra KJ, Bureau Y, Hou J, Raheb H, Cernvosky Z, Badmeav V, Copen J, Husni M and Woodbury-Farina M. Liposomal-formulated curcumin [Lipocurc] targeting HDAC (histone deacetylase) prevents apoptosis and improves motor deficits in Park 7 (DJ-1)-knockout rat model of Parkinson’s disease: implications for epigenetics-based nanotechnology-driven drug platform. J Complement Integr Med 2013; 10.
57. [57] Jaisin Y, Thampithak A, Meesarapee B, Ratanachamnong P, Suksamrarn A, Phivthong-Ngam L, Phumala-Morales N, Chongthammakun S, Govitrapong P and Sanvarinda Y. Curcumin I protects the dopaminergic cell line SH-SY5Y from 6-hydroxydopamine-induced neurotoxicity through attenuation of p53-mediated apoptosis. Neurosci Lett 2011; 489: 192-196.
58. [58] Kim HT, Qiang W, Liu N, Scofield VL, Wong PK and Stoica G. Up-regulation of astrocyte cyclooxygenase-2, CCAAT/enhancer-binding protein-homology protein, glucose-related protein 78, eukaryotic initiation factor 2 alpha, and c-Jun N-terminal kinase by a neurovirulent murine retrovirus. J Neurovirol 2005; 11: 166-179.
59. [59] Sawada H, Ibi M, Kihara T, Honda K, Nakamizo T, Kanki R, Nakanishi M, Sakka N, Akaike A and Shimohama S. Estradiol protects dopaminergic neurons in a MPP+Parkinson’s disease model. Neuropharmacology 2002; 42: 1056-1064.
60. [60] Jiang TF, Zhang YJ, Zhou HY, Wang HM, Tian LP, Liu J, Ding JQ and Chen SD. Curcumin ameliorates the neurodegenerative pathology in A53T alpha-synuclein cell model of Parkinson’s disease through the downregulation of mTOR/p70S6K signaling and the recovery of macroautophagy. J Neuroimmune Pharmacol 2013; 8: 356-369.
61. [61] Zbarsky V, Datla KP, Parkar S, Rai DK, Aruoma OI and Dexter DT. Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson’s disease. Free Radic Res 2005; 39: 1119-1125.
62. [62] Jagatha B, Mythri RB, Vali S and Bharath MM. Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: therapeutic implications for Parkinson’s disease explained via in silico studies. Free Radic Biol Med 2008; 44: 907-917.
63. [63] Harish G, Venkateshappa C, Mythri RB, Dubey SK, Mishra K, Singh N, Vali S and Bharath MM. Bioconjugates of curcumin display improved protection against glutathione depletion mediated oxidative stress in a dopaminergic neuronal cell line: Implications for Parkinson’s disease. Bioorg Med Chem 2010; 18: 2631-2638.
64. [64] Agrawal SS, Gullaiya S, Dubey V, Singh V, Kumar A, Nagar A and Tiwari P. Neurodegenerative Shielding by Curcumin and Its Derivatives on Brain Lesions Induced by 6-OHDA Model of Parkinson’s Disease in Albino Wistar Rats. Cardiovasc Psychiatry Neurol 2012; 2012: 942981.
65. [65] Meesarapee B, Thampithak A, Jaisin Y, Sanvarinda P, Suksamrarn A, Tuchinda P, Morales NP and Sanvarinda Y. Curcumin I mediates neuroprotective effect through attenuation of quinoprotein formation, p-p38 MAPK expression, and caspase-3 activation in 6-hydroxydopamine treated SH-SY5Y cells. Phytother Res 2014; 28: 611-616.
66. [66] Jayaraj RL, Tamilselvam K, Manivasagam T and Elangovan N. Neuroprotective effect of CNB-001, a novel pyrazole derivative of curcumin on biochemical and apoptotic markers against rotenone-induced SK-N-SH cellular model of Parkinson’s disease. J Mol Neurosci 2013; 51: 863-870.
67. [67] Mythri RB, Harish G, Dubey SK, Misra K and Bharath MM. Glutamoyl diester of the dietary polyphenol curcumin offers improved protection against peroxynitrite-mediated nitrosative stress and damage of brain mitochondria in vitro: implications for Parkinson’s disease. Mol Cell Biochem 2011; 347: 135-143.
68. [68] Liu Z, Yu Y, Li X, Ross CA and Smith WW. Curcumin protects against A53T alpha-synucleininduced toxicity in a PC12 inducible cell model for Parkinsonism. Pharmacol Res 2011; 63: 439-444.
69. [69] Beal MF. Therapeutic approaches to mitochondrial dysfunction in Parkinson’s disease. Parkinsonism Relat Disord 2009; 15 Suppl 3: S189-194.
70. [70] Du XX, Xu HM, Jiang H, Song N, Wang J and Xie JX. Curcumin protects nigral dopaminergic neurons by iron-chelation in the 6-hydroxydopamine rat model of Parkinson’s disease. Neurosci Bull 2012; 28: 253-258.
71. [71] Ji HF, Shen L. The multiple pharmaceutical potential of curcumin in Parkinson’s disease. CNS Neurol Disord Drug Targets 2014; 13: 369-373.
72. [72] Ono K, Hirohata M and Yamada M. Alpha-synuclein assembly as a therapeutic target of Parkinson’s disease and related disorders. Curr Pharm Des 2008; 14: 3247-3266.
73. [73] Gadad BS, Subramanya PK, Pullabhatla S, Shantharam IS and Rao KS. Curcumin-glucoside, a novel synthetic derivative of curcumin, inhibits alpha-synuclein oligomer formation: relevance to Parkinson’s disease. Curr Pharm Des 2012; 18: 76-84.
74. [74] Singh PK, Kotia V, Ghosh D, Mohite GM, Kumar A and Maji SK. Curcumin modulates alphasynuclein aggregation and toxicity. ACS Chem Neurosci 2013; 4: 393-407.
75. [75] Gautam S, Karmakar S, Bose A and Chowdhury PK. β-cyclodextrin and curcumin, a potent cocktail for disaggregating and/or inhibiting amyloids: a case study with alpha-synuclein. Biochemistry 2014; 53: 4081-4083.
76. [76] Rajeswari A and Sabesan M. Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson’s disease induced by MPTP neurodegeneration in mice. Inflammopharmacology 2008; 16: 96-99.
77. [77] Verma M, Sharma A, Naidu S, Bhadra AK, Kukreti R and Taneja V. Curcumin prevents formation of polyglutamine aggregates by inhibiting Vps36, a component of the ESCRT-II complex. PLoS One 2012; 7: e42923.
78. [78] Ortiz-Ortiz MA, Moran JM, Ruiz-Mesa LM, Niso-Santano M, Bravo-SanPedro JM, Gomez-Sanchez R, Gonzalez-Polo RA and Fuentes JM. Curcumin exposure induces expression of the Parkinson’s disease-associated leucine-rich repeat kinase 2 (LRRK2) in rat mesencephalic cells. Neurosci Lett 2010; 468: 120-124.
79. [79] Yang D, Li T, Liu Z, Arbez N, Yan J, Moran TH, Ross CA and Smith WW. LRRK2 kinase activity mediates toxic interactions between genetic mutation and oxidative stress in a Drosophila model: suppression by curcumin. Neurobiol Dis 2012; 47: 385-392.
80. [80] Lee KW, Jung SY, Choi SM and Yang EJ. Effects of ginsenoside Re on LPS-induced inflammatory mediators in BV2 microglial cells. BMC Complement Altern Med 2012; 12: 196.
81. [81] Kim SN, Ha YW, Shin H, Son SH, Wu SJ and Kim YS. Simultaneous quantification of 14 ginsenosides in Panax ginseng C.A. Meyer (Korean red ginseng) by HPLC-ELSD and its application to quality control. J Pharm Biomed Anal 2007; 45: 164-170.
82. [82] Lee YY, Park JS, Jung JS, Kim DH and Kim HS. Anti-Inflammatory Effect of Ginsenoside Rg5 in Lipopolysaccharide-Stimulated BV2 Microglial Cells. Int J Mol Sci 2013; 14: 9820-9833.
83. [83] Kim KH, Song K, Yoon SH, Shehzad O, Kim YS and Son JH. Rescue of PINK1 protein null-specific mitochondrial complex IV deficits by ginsenoside Re activation of nitric oxide signaling. J Biol Chem 2012; 287: 44109-44120.
84. [84] Liu Q, Kou JP and Yu BY. Ginsenoside Rg1 protects against hydrogen peroxide-induced cell death in PC12 cells via inhibiting NF-kappaB activation. Neurochem Int 2011; 58: 119-125.
85. [85] Lin WM, Zhang YM, Moldzio R and Rausch WD. Ginsenoside Rd attenuates neuroinflammation of dopaminergic cells in culture. J Neural Transm Suppl 2007; 72: 105-112.
86. [86] Park SM, Choi MS, Sohn NW and Shin JW. Ginsenoside Rg3 attenuates microglia activation following systemic lipopolysaccharide treatment in mice. Biol Pharm Bull 2012; 35: 1546-1552.
87. [87] Chen XC, Zhu YG, Zhu LA, Huang C, Chen Y, Chen LM, Fang F, Zhou YC and Zhao CH. Ginsenoside Rg1 attenuates dopamine-induced apoptosis in PC12 cells by suppressing oxidative stress. Eur J Pharmacol 2003; 473: 1-7.
88. [88] Leung KW, Yung KK, Mak NK, Chan YS, Fan TP and Wong RN. Neuroprotective effects of ginsenoside-Rg1 in primary nigral neurons against rotenone toxicity. Neuropharmacology 2007; 52: 827-835.
89. [89] Xu BB, Liu CQ, Gao X, Zhang WQ, Wang SW and Cao YL. Possible mechanisms of the protection of ginsenoside Re against MPTP-induced apoptosis in substantia nigra neurons of Parkinson’s disease mouse model. J Asian Nat Prod Res 2005; 7: 215-224.
90. [90] Xu H, Jiang H, Wang J and Xie J. Rg1 protects iron-induced neurotoxicity through antioxidant and iron regulatory proteins in 6-OHDA-treated MES23.5 cells. J Cell Biochem 2010; 111: 1537-1545.
91. [91] Xu H, Jiang H, Wang J and Xie J. Rg1 protects the MPP+-treated MES23.5 cells via attenuating DMT1 up-regulation and cellular iron uptake. Neuropharmacology 2010; 58: 488-494.
92. [92] Rudakewich M, Ba F and Benishin CG. Neurotrophic and neuroprotective actions of ginsenosides Rb(1) and Rg(1). Planta Med 2001; 67: 533-537.
93. [93] Witkin JM and Li X. Curcumin, an active constiuent of the ancient medicinal herb Curcuma longa L.: some uses and the establishment and biological basis of medical efficacy. CNS Neurol Disord Drug Targets 2013; 12: 487-497.
94. [94] Song JX, Sze SC, Ng TB, Lee CK, Leung GP, Shaw PC, Tong Y and Zhang YB. Anti-Parkinsonian drug discovery from herbal medicines: what have we got from neurotoxic models? J Ethnopharmacol 2012; 139: 698-711.